Sign in
Active, not recruitingPhase 2

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Key facts

Who runs it
Neurocrine Switzerland GmbH
Where
Germany3 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
7 people enrolled
Started
30 Sept 2025
Expected to end
4 Oct 2029
Type of study
Interventional
Treatments tested
  • Crinecerfont
Record updated
28 August 2026

Who can take part

Age
0 years to 23 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Be a female or male between 0 to <2 years of age at screening
  • Have a medically confirmed diagnosis of classic CAH (salt wasting or simple virilizing) due to 21-hydroxylase deficiency (21-OHD)
  • Be on a clinically stable regimen of hydrocortisone (and fludrocortisone, if applicable) treatment

Who cannot take part

  • Have any condition besides CAH that requires chronic daily therapy with orally administered steroids
  • Have any other clinically significant medical condition or chronic disease; Note: Other protocol-defined inclusion and exclusion criteria may apply
  • Have a known or suspected diagnosis of any of the other forms of classic CAH

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to <2 years of age with congenital adrenal hyperplasia (CAH).

The group in the trial

  • CrinecerfontTreatment being tested

    Participants with CAH will receive crinecerfont during an initial 14-day treatment period, followed by an optional 36-month open-label extension (OLE).

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia
Record updated
28 August 2026
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old (NCT07187375) – Frontlight Research